The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer
2 days ago · The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer — Novel weapons to counter endocrine therapy resistance and treat progressive disease
Current Treatment Approaches in HER2+ Metastatic Breast Cancer
Jun 17, 2025 · Panelists discussed how evolving strategies in HER2-positive metastatic breast cancer are shifting toward more personalized maintenance approaches, including the integration of CDK4/6 …
Systemic treatment for HER2-positive metastatic breast cancer
May 7, 2025 · The treatment of HER2-positive metastatic breast cancer is reviewed here. An overview of the approach to metastatic breast cancer, HER2 as a predictive marker, endocrine therapy for …
HER2-Targeted Therapies for Metastatic Breast Cancer
Mar 3, 2025 · HER2-Targeted Therapies for Metastatic Breast Cancer Watch our June 2024 MBC Impact Series, Metastatic HER2-Positive Breast Cancer. HER2 and metastatic breast cancer The …
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease ...
4 days ago · Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) …
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in ...
4 days ago · Abstract Purpose: The HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line …
New Treatments Approved for Early and Metastatic Breast Cancer
Aug 4, 2025 · Kisqali: Two combinations approved for treating high-risk, early-stage HR-positive breast cancer. Datroway: Approved for certain metastatic breast cancers. Itovebi: Approved as a combined …
Enhertu/Perjeta Combo Enhances Quality of in HER2+ Advanced Breast Cancer
2 days ago · The DESTINY-Breast09 trial compared Enhertu plus Perjeta to the standard-of-care regimen of trastuzumab (Herceptin), Perjeta, and taxane as first-line therapy for patients with HER2 …
Tucatinib Plus Trastuzumab/Pertuzumab Prolongs PFS in HER2-Positive ...
3 days ago · As such, there is an unmet need for developing more effective first-line maintenance treatments in HER2-positive metastatic breast cancer.
Pfizer makes first-line case for Tukysa in breast cancer
2 days ago · Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.